rawfin.tv
Merck, Gilead Sciences Announce Phase 3 Study Update
MarketsstocksAI Generated

Merck, Gilead Sciences Announce Phase 3 Study Update

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Merck and Gilead Sciences provided an update on their ongoing Phase 3 KEYNOTE-D46/EVOKE-03 study. The announcement pertains to the clinical development of their joint therapeutic efforts.

MerckGilead SciencesPharmaceuticalsClinical TrialsBiotech

Related Articles

S&P 500 Heavyweights Face Earnings Test Amid Fed Meeting

S&P 500 Heavyweights Face Earnings Test Amid Fed Meeting

stocks
China Equities Lag US Stocks by Record 2.095 Valuation Ratio

China Equities Lag US Stocks by Record 2.095 Valuation Ratio

stocks
S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks